AU2003241322A1 - Multi-phasic delivery via transmucosal absorption of antiemetic medicaments - Google Patents

Multi-phasic delivery via transmucosal absorption of antiemetic medicaments

Info

Publication number
AU2003241322A1
AU2003241322A1 AU2003241322A AU2003241322A AU2003241322A1 AU 2003241322 A1 AU2003241322 A1 AU 2003241322A1 AU 2003241322 A AU2003241322 A AU 2003241322A AU 2003241322 A AU2003241322 A AU 2003241322A AU 2003241322 A1 AU2003241322 A1 AU 2003241322A1
Authority
AU
Australia
Prior art keywords
delivery via
transmucosal absorption
via transmucosal
antiemetic
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003241322A
Other versions
AU2003241322A8 (en
Inventor
Edward J. Cone
John M. Pinney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NPD LLC
Original Assignee
NPD LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPD LLC filed Critical NPD LLC
Publication of AU2003241322A1 publication Critical patent/AU2003241322A1/en
Publication of AU2003241322A8 publication Critical patent/AU2003241322A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003241322A 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments Abandoned AU2003241322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37626302P 2002-04-30 2002-04-30
US60/376,263 2002-04-30
PCT/US2003/013255 WO2003092591A2 (en) 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments

Publications (2)

Publication Number Publication Date
AU2003241322A1 true AU2003241322A1 (en) 2003-11-17
AU2003241322A8 AU2003241322A8 (en) 2003-11-17

Family

ID=29401323

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003241322A Abandoned AU2003241322A1 (en) 2002-04-30 2003-04-30 Multi-phasic delivery via transmucosal absorption of antiemetic medicaments

Country Status (2)

Country Link
AU (1) AU2003241322A1 (en)
WO (1) WO2003092591A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US7658945B2 (en) * 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US20080187589A1 (en) * 2007-02-05 2008-08-07 Pinney John M Multi-modal delivery via transmucosal and gastro-intestinal absorption of antihistamines and symptom relief
US9855227B2 (en) 2015-12-18 2018-01-02 The Procter & Gamble Company Quick dissolving diphenhydramine oral dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
JP3908795B2 (en) * 1994-11-29 2007-04-25 久光製薬株式会社 Ketotifen-containing transdermal preparation
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods

Also Published As

Publication number Publication date
WO2003092591A2 (en) 2003-11-13
WO2003092591A3 (en) 2004-03-25
AU2003241322A8 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
IL165480A0 (en) Topical drug delivery using phosphatidylcholine
AU2003210001A1 (en) Medicament delivery device
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2002331743A1 (en) Handheld medication dosage calculator
AU2003218233A1 (en) Bioadhesive drug delivery system
AU2003299849A1 (en) Drug delivery apparatus
AU2003281752A1 (en) Medicament dispenser
AU2003254590A1 (en) Medicament dispenser
AU2003246734A1 (en) Medicament dispenser
AU2003222067A1 (en) System for delivery of therapeutic substances
AU2003217820A1 (en) Periocular drug delivery for diabetic retinopathy
AU2003300469A1 (en) Methods for making pharmaceutical dosage forms containing active cushioning components
AU2003228400A1 (en) Medicant package
AU2003230785A1 (en) Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
AU2003276572A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
AU2003231260A1 (en) Catechin multimers as therapeutic drug delivery agents
AU2001292865A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
AU2003241322A1 (en) Multi-phasic delivery via transmucosal absorption of antiemetic medicaments
AU2003233083A1 (en) Medicament dispenser
GB0228305D0 (en) Therapeutic composition for respiratory delivery
AUPS286302A0 (en) Medication inhaler
AU2003280799A1 (en) Medicinal composition
AU2003201886A1 (en) Medicinal compositions for improving oral absorption
AU2001274236A1 (en) Dry-powder pharmaceutical formulation for inhalation comprising alpha4-intergrinantagonist
AU2002330801A1 (en) Method for oral transmucosal delivery of interferon

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase